Sector Update: Health Care Stocks Flat to Lower Premarket Monday

MT Newswires Live

06-23

Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the iShares Biotechnology ETF (IBB) inactive.

Novo Nordisk (NVO) said it has halted its collaboration with Hims & Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims & Hers Health shares were down more than 23% pre-bell.

Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a "statistically significant" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.

Cidara Therapeutics (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545441261"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545441261\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545441261?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545441261","market":"fut","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Flat to Lower Premarket Monday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) inactive.</p><p>Novo Nordisk (NVO) said it has halted its collaboration with Hims &amp; Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims &amp; Hers Health shares were down more than 23% pre-bell.</p><p>Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.</p><p>Cidara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Flat to Lower Premarket Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Flat to Lower Premarket Monday\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-23 21:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) inactive.</p><p>Novo Nordisk (NVO) said it has halted its collaboration with Hims &amp; Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims &amp; Hers Health shares were down more than 23% pre-bell.</p><p>Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.</p><p>Cidara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545441261","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545441261","pubTimestamp":1750684354,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund  declining 0.2% and the iShares Biotechnology ETF  inactive.Novo Nordisk  said it has halted its collaboration with Hims & Hers Health  on the sale of weight loss drugs, including Wegovy. Hims & Hers Health shares were down more than 23% pre-bell.Exelixis  shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.Cidara Therapeutics  shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"行业更新：周一盘前医疗保健股持平或走低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDTX":0.9,"EXEL":0.9,"HIMS":0.9,"IBB":0.9,"NVO":0.9,"NVO.AU":1,"XLV":0.9},"content_text":"Health care stocks were flat to lower premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) declining 0.2% and the iShares Biotechnology ETF (IBB) inactive.Novo Nordisk (NVO) said it has halted its collaboration with Hims & Hers Health (HIMS) on the sale of weight loss drugs, including Wegovy. Hims & Hers Health shares were down more than 23% pre-bell.Exelixis (EXEL) shares were advancing more than 21% after the company said its phase 3 Stellar-303 trial showed a \"statistically significant\" overall survival benefit in the combination of zanzalintinib and atezolizumab in patients with a type of metastatic colorectal cancer.Cidara Therapeutics (CDTX) shares were up more than 94% after the company said its phase 2b trial of CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64 met its primary endpoint and all secondary efficacy endpoints for all dose groups.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}